BR112013008749A2 - análogos de ciclosporina - Google Patents

análogos de ciclosporina

Info

Publication number
BR112013008749A2
BR112013008749A2 BR112013008749A BR112013008749A BR112013008749A2 BR 112013008749 A2 BR112013008749 A2 BR 112013008749A2 BR 112013008749 A BR112013008749 A BR 112013008749A BR 112013008749 A BR112013008749 A BR 112013008749A BR 112013008749 A2 BR112013008749 A2 BR 112013008749A2
Authority
BR
Brazil
Prior art keywords
cyclosporine analogs
cyclosporine
analogs
conditions
methods
Prior art date
Application number
BR112013008749A
Other languages
English (en)
Portuguese (pt)
Inventor
S Schaumburg Christopher
Arthur Scowen David
E Garst Michael
E Stern Michael
Robert Carling William
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112013008749A2 publication Critical patent/BR112013008749A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013008749A 2010-10-12 2011-10-11 análogos de ciclosporina BR112013008749A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39245110P 2010-10-12 2010-10-12
PCT/US2011/055788 WO2012051193A1 (en) 2010-10-12 2011-10-11 Cyclosporin analogs

Publications (1)

Publication Number Publication Date
BR112013008749A2 true BR112013008749A2 (pt) 2019-09-24

Family

ID=44883796

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013008749A BR112013008749A2 (pt) 2010-10-12 2011-10-11 análogos de ciclosporina

Country Status (12)

Country Link
US (2) US9175042B2 (https=)
EP (1) EP2627663B1 (https=)
JP (1) JP5805773B2 (https=)
KR (1) KR20140026328A (https=)
CN (1) CN103261212A (https=)
AU (1) AU2011316689B2 (https=)
BR (1) BR112013008749A2 (https=)
CA (1) CA2814191A1 (https=)
IL (1) IL225616A0 (https=)
MX (1) MX2013004062A (https=)
RU (1) RU2013120927A (https=)
WO (1) WO2012051193A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010138422A1 (en) * 2009-05-27 2010-12-02 Allergan, Inc. Cyclosporin derivatives for enhancing the growth of hair
WO2012079172A1 (en) * 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Cyclosporine analogue molecules modified at amino acid 1 and 3
JP2015519368A (ja) * 2012-06-01 2015-07-09 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ シクロスポリンａ類似体
WO2014138425A1 (en) 2013-03-08 2014-09-12 Allergan, Inc. Cyclosporine a-steroid conjugates
US9914755B2 (en) 2015-01-08 2018-03-13 Allergan, Inc. Cyclosporin derivatives wherein the MeBmt sidechain has been cyclized
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
EP3554346B1 (en) 2016-12-14 2024-01-31 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immunosuppressant
WO2019246312A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CN115028681B (zh) * 2022-08-11 2022-11-15 中国科学院微生物研究所 一种降解亲环素a的嵌合体化合物及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
FR2757521B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2757522B1 (fr) * 1996-12-24 1999-01-29 Rhone Poulenc Rorer Sa Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2762843B1 (fr) * 1997-04-30 1999-12-10 Rhone Poulenc Rorer Sa Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2772768B1 (fr) * 1997-12-19 2000-01-14 Rhone Poulenc Rorer Sa Nouveau procede de preparation de derives de cyclosporine
PT1086124E (pt) 1998-06-12 2004-04-30 Chem Ag C Ciclosporinas novas
US6254860B1 (en) * 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
CN100478025C (zh) * 2005-03-25 2009-04-15 中国科学院上海药物研究所 一种环孢菌素a眼用微乳制剂及其制备方法
DK2023918T3 (da) * 2006-05-19 2011-04-26 Scynexis Inc Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
CA2686234A1 (en) * 2007-05-04 2008-11-13 Allergan, Inc. Use of cyclosporines in the treatment of patients with intraocular lenses
KR20110031973A (ko) 2008-07-10 2011-03-29 알러간, 인코포레이티드 눈 및 피부의 질환 및 상태를 치료하기 위한 사이클로스포린 유도체
WO2012009715A2 (en) * 2010-07-16 2012-01-19 S&T Global Inc. Novel cyclosporin derivatives for the treatment and prevention of a viral infection
US9573978B2 (en) * 2010-08-12 2017-02-21 S&T Global, Inc. Cyclosporin derivatives for the treatment and prevention of a viral infection
BR112013008864A2 (pt) 2010-10-12 2016-06-28 Allergan Inc análogos d ciclosporina
PT2646043T (pt) 2010-12-03 2017-05-09 S&T Global Inc Novos derivados ciclosporina para o tratamento e prevenção de uma infeção viral
US9890198B2 (en) 2010-12-03 2018-02-13 S&T Global Inc. Cyclosporin derivatives and uses thereof

Also Published As

Publication number Publication date
US9175042B2 (en) 2015-11-03
US9561259B2 (en) 2017-02-07
RU2013120927A (ru) 2014-11-20
JP5805773B2 (ja) 2015-11-10
MX2013004062A (es) 2013-07-22
EP2627663B1 (en) 2018-02-21
CN103261212A (zh) 2013-08-21
AU2011316689B2 (en) 2016-07-14
CA2814191A1 (en) 2012-04-19
WO2012051193A1 (en) 2012-04-19
IL225616A0 (en) 2013-06-27
KR20140026328A (ko) 2014-03-05
US20120135939A1 (en) 2012-05-31
EP2627663A1 (en) 2013-08-21
US20160022765A1 (en) 2016-01-28
AU2011316689A1 (en) 2013-05-02
JP2013544786A (ja) 2013-12-19

Similar Documents

Publication Publication Date Title
BR112013008749A2 (pt) análogos de ciclosporina
CO7151535A2 (es) Evento de maiz mon 87411
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
EA201401077A1 (ru) Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
CA2900335C (en) Synthetic analogs of epipolythiodioxopiperazines and uses thereof
BR112012024312A2 (pt) anticorpos biespecíficos
UY34811A (es) Compuestos y composiciones para inhibir la actividad de la abl1, abl2 y bcr-abl1
UY35210A (es) Inhibidores de autotaxina
BR112015022191A8 (pt) compostos heteroarila e usos dos mesmos
MX374399B (es) Composiciones y sus usos para tratar y prevenir la enfermedad de huntington.
UY34697A (es) Métodos para preparar análogos de nucleótidos
MX2018009553A (es) Metodos de seleccion.
BR112014005744A2 (pt) composições de peptídeo glucagon-like-2 e métodos para sua produção e utilização
UY34210A (es) Composiciones, métodos y sistemas para la micropropagación de plantas
UY34885A (es) Proteínas de unión anti-mesotelina
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MX2013004061A (es) Analogos de ciclosporina.
MX391043B (es) Formulaciones de anticuerpo y metodos.
JO3154B1 (ar) عوامل مضادة لـ trpv4
WO2012129341A3 (en) Disease detection in plants
BR112014017673A8 (pt) Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
BR112015014453A2 (pt) produtos de cuidado oral compreendendo cloreto de zinco tetrabásico e trimetilglicina
BR112015008824A2 (pt) linhagens melhoradas de microalgas e processo das mesmas
BR112014005935A2 (pt) derivados de anilina, sua preparação e sua aplicação terapêutica
EA201491609A1 (ru) Модуляторы x рецепторов печени

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.